Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

Alan M. Stamm, Robert B Diasio, William E. Dismukes, Smith Shadomy, Gretchen A. Cloud, Cynthia A. Bowles, George H. Karam, Ana Espinel-Ingroff

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

A multicenter prospective randomized trial of four versus six weeks of amphotericin B, 0.3 mg/kg per day, plus flucytosine, 150 mg/kg per day, was performed with 194 patients with cryptococcal meningitis. One or more toxic drug reactions developed in 103 patients: azotemia (51), renal tubular acidosis (two), leukopenia (30), thrombocytopenia (22), diarrhea (26), nausea/vomiting (10), and hepatitis (13). The four- and six-week regimens were complicated by toxicity in 44 percent and 43 percent of cases, respectively. Toxicity appeared during the first two weeks of therapy in 56 percent and during the first four weeks in 87 percent. Azotemia did not occur more frequently in renal transplant recipients or diabetic patients. Cytopenias did not appear more often in patients with hematologic malignancies or those receiving immunosuppressive therapies. Toxic reactions that contributed to death developed in five patients (two with azotemia, one with pancytopenia, one with hepatitis, one with ileus). Amphotericin B- induced azotemia was not a significant risk factor for the subsequent development of bone marrow, gastrointestinal, or hepatic toxicity attributable to flucytosine. Flucytosine toxocity was associated with peak serum flucytosine levels of 100 μg/ml or more during two or more weeks of therapy (p = 0.005). Peak 5-fluorouracil levels were not predictive of toxicity. An initial dose of flucytosine is recommended based on the creatinine clearance: 150 mg/kg per day at a creatinine clearance above 50 ml/minute, 75 mg/kg per day at a creatinine clearance of 26 to 50 ml/minute, and 37 mg/kg per day at a creatinine clearance of 13 to 25 ml/minute. The serum creatinine leve should be monitored twice weekly and the creatinine clearance weekly during therapy in order to anticipate changes in serum flucytosine concentration. In addition, it is recommended that the serum flucytosine level be determined two hours after an oral dose once a week, and that the dose be adjusted to maintain a level of 50 to 100 μg/ml.

Original languageEnglish (US)
Pages (from-to)236-242
Number of pages7
JournalThe American journal of medicine
Volume83
Issue number2
DOIs
StatePublished - 1987
Externally publishedYes

Fingerprint

Cryptococcal Meningitis
Flucytosine
Amphotericin B
Azotemia
Creatinine
Poisons
Serum
Hepatitis
Renal Tubular Acidosis
Pancytopenia
Ileus
Leukopenia
Hematologic Neoplasms
Therapeutics
Immunosuppressive Agents
Fluorouracil
Thrombocytopenia
Nausea
Vomiting
Diarrhea

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Stamm, A. M., Diasio, R. B., Dismukes, W. E., Shadomy, S., Cloud, G. A., Bowles, C. A., ... Espinel-Ingroff, A. (1987). Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. The American journal of medicine, 83(2), 236-242. https://doi.org/10.1016/0002-9343(87)90691-7

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. / Stamm, Alan M.; Diasio, Robert B; Dismukes, William E.; Shadomy, Smith; Cloud, Gretchen A.; Bowles, Cynthia A.; Karam, George H.; Espinel-Ingroff, Ana.

In: The American journal of medicine, Vol. 83, No. 2, 1987, p. 236-242.

Research output: Contribution to journalArticle

Stamm, AM, Diasio, RB, Dismukes, WE, Shadomy, S, Cloud, GA, Bowles, CA, Karam, GH & Espinel-Ingroff, A 1987, 'Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis', The American journal of medicine, vol. 83, no. 2, pp. 236-242. https://doi.org/10.1016/0002-9343(87)90691-7
Stamm, Alan M. ; Diasio, Robert B ; Dismukes, William E. ; Shadomy, Smith ; Cloud, Gretchen A. ; Bowles, Cynthia A. ; Karam, George H. ; Espinel-Ingroff, Ana. / Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. In: The American journal of medicine. 1987 ; Vol. 83, No. 2. pp. 236-242.
@article{13c7d9ab728344d6906047d4967fd3f2,
title = "Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis",
abstract = "A multicenter prospective randomized trial of four versus six weeks of amphotericin B, 0.3 mg/kg per day, plus flucytosine, 150 mg/kg per day, was performed with 194 patients with cryptococcal meningitis. One or more toxic drug reactions developed in 103 patients: azotemia (51), renal tubular acidosis (two), leukopenia (30), thrombocytopenia (22), diarrhea (26), nausea/vomiting (10), and hepatitis (13). The four- and six-week regimens were complicated by toxicity in 44 percent and 43 percent of cases, respectively. Toxicity appeared during the first two weeks of therapy in 56 percent and during the first four weeks in 87 percent. Azotemia did not occur more frequently in renal transplant recipients or diabetic patients. Cytopenias did not appear more often in patients with hematologic malignancies or those receiving immunosuppressive therapies. Toxic reactions that contributed to death developed in five patients (two with azotemia, one with pancytopenia, one with hepatitis, one with ileus). Amphotericin B- induced azotemia was not a significant risk factor for the subsequent development of bone marrow, gastrointestinal, or hepatic toxicity attributable to flucytosine. Flucytosine toxocity was associated with peak serum flucytosine levels of 100 μg/ml or more during two or more weeks of therapy (p = 0.005). Peak 5-fluorouracil levels were not predictive of toxicity. An initial dose of flucytosine is recommended based on the creatinine clearance: 150 mg/kg per day at a creatinine clearance above 50 ml/minute, 75 mg/kg per day at a creatinine clearance of 26 to 50 ml/minute, and 37 mg/kg per day at a creatinine clearance of 13 to 25 ml/minute. The serum creatinine leve should be monitored twice weekly and the creatinine clearance weekly during therapy in order to anticipate changes in serum flucytosine concentration. In addition, it is recommended that the serum flucytosine level be determined two hours after an oral dose once a week, and that the dose be adjusted to maintain a level of 50 to 100 μg/ml.",
author = "Stamm, {Alan M.} and Diasio, {Robert B} and Dismukes, {William E.} and Smith Shadomy and Cloud, {Gretchen A.} and Bowles, {Cynthia A.} and Karam, {George H.} and Ana Espinel-Ingroff",
year = "1987",
doi = "10.1016/0002-9343(87)90691-7",
language = "English (US)",
volume = "83",
pages = "236--242",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

AU - Stamm, Alan M.

AU - Diasio, Robert B

AU - Dismukes, William E.

AU - Shadomy, Smith

AU - Cloud, Gretchen A.

AU - Bowles, Cynthia A.

AU - Karam, George H.

AU - Espinel-Ingroff, Ana

PY - 1987

Y1 - 1987

N2 - A multicenter prospective randomized trial of four versus six weeks of amphotericin B, 0.3 mg/kg per day, plus flucytosine, 150 mg/kg per day, was performed with 194 patients with cryptococcal meningitis. One or more toxic drug reactions developed in 103 patients: azotemia (51), renal tubular acidosis (two), leukopenia (30), thrombocytopenia (22), diarrhea (26), nausea/vomiting (10), and hepatitis (13). The four- and six-week regimens were complicated by toxicity in 44 percent and 43 percent of cases, respectively. Toxicity appeared during the first two weeks of therapy in 56 percent and during the first four weeks in 87 percent. Azotemia did not occur more frequently in renal transplant recipients or diabetic patients. Cytopenias did not appear more often in patients with hematologic malignancies or those receiving immunosuppressive therapies. Toxic reactions that contributed to death developed in five patients (two with azotemia, one with pancytopenia, one with hepatitis, one with ileus). Amphotericin B- induced azotemia was not a significant risk factor for the subsequent development of bone marrow, gastrointestinal, or hepatic toxicity attributable to flucytosine. Flucytosine toxocity was associated with peak serum flucytosine levels of 100 μg/ml or more during two or more weeks of therapy (p = 0.005). Peak 5-fluorouracil levels were not predictive of toxicity. An initial dose of flucytosine is recommended based on the creatinine clearance: 150 mg/kg per day at a creatinine clearance above 50 ml/minute, 75 mg/kg per day at a creatinine clearance of 26 to 50 ml/minute, and 37 mg/kg per day at a creatinine clearance of 13 to 25 ml/minute. The serum creatinine leve should be monitored twice weekly and the creatinine clearance weekly during therapy in order to anticipate changes in serum flucytosine concentration. In addition, it is recommended that the serum flucytosine level be determined two hours after an oral dose once a week, and that the dose be adjusted to maintain a level of 50 to 100 μg/ml.

AB - A multicenter prospective randomized trial of four versus six weeks of amphotericin B, 0.3 mg/kg per day, plus flucytosine, 150 mg/kg per day, was performed with 194 patients with cryptococcal meningitis. One or more toxic drug reactions developed in 103 patients: azotemia (51), renal tubular acidosis (two), leukopenia (30), thrombocytopenia (22), diarrhea (26), nausea/vomiting (10), and hepatitis (13). The four- and six-week regimens were complicated by toxicity in 44 percent and 43 percent of cases, respectively. Toxicity appeared during the first two weeks of therapy in 56 percent and during the first four weeks in 87 percent. Azotemia did not occur more frequently in renal transplant recipients or diabetic patients. Cytopenias did not appear more often in patients with hematologic malignancies or those receiving immunosuppressive therapies. Toxic reactions that contributed to death developed in five patients (two with azotemia, one with pancytopenia, one with hepatitis, one with ileus). Amphotericin B- induced azotemia was not a significant risk factor for the subsequent development of bone marrow, gastrointestinal, or hepatic toxicity attributable to flucytosine. Flucytosine toxocity was associated with peak serum flucytosine levels of 100 μg/ml or more during two or more weeks of therapy (p = 0.005). Peak 5-fluorouracil levels were not predictive of toxicity. An initial dose of flucytosine is recommended based on the creatinine clearance: 150 mg/kg per day at a creatinine clearance above 50 ml/minute, 75 mg/kg per day at a creatinine clearance of 26 to 50 ml/minute, and 37 mg/kg per day at a creatinine clearance of 13 to 25 ml/minute. The serum creatinine leve should be monitored twice weekly and the creatinine clearance weekly during therapy in order to anticipate changes in serum flucytosine concentration. In addition, it is recommended that the serum flucytosine level be determined two hours after an oral dose once a week, and that the dose be adjusted to maintain a level of 50 to 100 μg/ml.

UR - http://www.scopus.com/inward/record.url?scp=0023634292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023634292&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(87)90691-7

DO - 10.1016/0002-9343(87)90691-7

M3 - Article

VL - 83

SP - 236

EP - 242

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -